...

首页> 外文期刊>Journal of Clinical Oncology >Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial

【24h】

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial

机译：拉帕替尼联合卡培他滨加奥沙利铂治疗人表皮生长因子受体2-阳性晚期或转移性胃，食管或胃食管腺癌：TRIO-013 / LOGiC-A随机III期试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2016年第5期|共12页
作者
Hecht J. Randolph; Bang Yung-Jue; Qin Shukui K.; Chung Hyun C.; Xu Jianming M.; Park Joon O.; Jeziorski Krzysztof; Shparyk Yaroslav; Hoff Paulo M.; Sobrero Alberto; Salman Pamela; Li Jin; Protsenko Svetlana A.; Wainberg Zev A.; Buyse Marc; Afenjar Karen; Houe Vincent; Garcia Agathe; Kaneko Tomomi; Huang Yingjie; Khan-Wasti Saba; Santillana Sergio; Press Michael F.; Slamon Dennis;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial [J] . Hecht J. Randolph, Bang Yung-Jue, Qin Shukui K., Journal of Clinical Oncology . 2016,第5期

机译：拉帕替尼联合卡培他滨加奥沙利铂治疗人表皮生长因子受体2-阳性晚期或转移性胃，食管或胃食管腺癌：TRIO-013 / LOGiC-A随机III期试验
2. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma [J] . Shah Manish A., Xu Rui-hua, Bang Yung-Jue, Journal of Clinical Oncology . 2017,第22期

机译：Hearoise：IIIB阶段随机化多中心研究比较与人体表皮生长因子受体2阳性转移性胃或胃食管反应腺癌腺癌腺癌腺癌腺癌腺癌患者的一线治疗和高剂量曲妥珠单抗
3. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer [J] . Pivot Xavier, Manikhas Alexey, Zurawski Bogdan, Journal of Clinical Oncology . 2015,第14期

机译：CEREBEL（EGF111438）：拉帕替尼加卡培他滨与曲妥珠单抗加卡培他滨对人类表皮生长因子受体2-阳性转移性乳腺癌患者的III期随机，开放标签研究
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized Double-Blind Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer—CALGB 40302 (Alliance) [O] . Harold J. Burstein, Constance T. Cirrincione, William T. Barry, -1

机译：有或没有抑制表皮生长因子受体和人表皮生长因子受体的内分泌治疗2：接受或不接受拉帕替尼的氟维沙坦的随机双盲安慰剂对照的Ⅲ期临床试验用于绝经后激素受体阳性的晚期乳腺癌女性。 CALGB 40302（联盟）
7. Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer [O] . Powles, Thomas, Huddart, Robert A, Elliott, Tony, 2017

机译：III期双盲，随机试验，比较了人表皮生长因子受体1/2阳性转移性膀胱癌患者在一线化疗后维持拉帕替尼与安慰剂的疗效

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号